| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882794 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 6 Pages |
Abstract
With the judicious use of plerixafor, nearly all patients can collect enough stem cells to proceed to transplantation. Further studies, including hematologic tolerance to posttransplantation therapy, are required to determine the cost-effectiveness of using plerixafor to convert adequate to more optimal mobilizers.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Dennis L. Cooper, Erin Medoff, Natalie Patel, Julie Baker, Kathryn Pratt, Francine Foss, Stuart E. Seropian, Sarah Perreault, Yanyun Wu,